Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Drugstore chain retailer, Rite Aid Corporation’s (RAD - Analyst Report) same-store sales (comps) for the four weeks ended Jan 26, 2013 inched up 0.3%. The rise was an outcome of an increase in front-end comps, offset by a decline in pharmacy comps.

Higher over-the-counter sales of flu-related products resulted in a 4.2% rise in the company’s front-end comps. Flu-related product sales contributed 2.4% to the growth in front-end comps. Despite a 5.0% increase in prescription counts at comparable stores, Pharmacy comps for January declined 1.4%. Pharmacy comps for the month was adversely impacted by about 665 basis points due to the introduction of new generic drugs. An increase of 3.4% in flu-related prescriptions and flu shots primarily prompted the growth in prescription counts.

Rite Aid reported total drugstore sales of $1.914 billion for the month, with prescription sales accounting for 68.9% of drugstore sales and third-party prescription sales making up for 96.2% of pharmacy sales. The company’s January sales declined 0.5% from the year-ago level of $1.923 billion.

Year-to-date, i.e. for the 47-week period ended on Jan 26, the company’s comps were up by a modest 0.1%, while net sales slipped 0.6% year over year to $22.826 billion. The increase in comps mainly came from a 1.6% rise in front-end comps partially offset by a 0.7% decrease in pharmacy comps. Meanwhile, prescription count at comparable stores jumped 3.7%.

Prescription sales comprised 67.5% of total drugstore sales. Additionally, third-party prescription sales accounted for 96.5% of pharmacy sales.

Our Recommendation

Rising estimates over the last 60 days – basically due to the company’s solid third-quarter fiscal 2013 results and revised bottom-line outlook – have helped Rite Aid to achieve a Zacks Rank #1 (Strong Buy).

Other drug store stocks that are performing well include CVS Caremark Corporation (CVS - Analyst Report), AmerisourceBergen Corporation (ABC - Analyst Report) and Cardinal Health Inc. (CAH - Analyst Report). These companies currently have a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%